Xu, Qianqian published the artcileApplication progress in CFTR inhibitors in the treatment of secretory diarrhea, Safety of 4-((4-Oxo-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-5-ylidene)methyl)benzoic acid, the publication is Zhongguo Yaoshi (Wuhan, China) (2015), 18(8), 1378-1382, database is CAplus.
A review. Secretory diarrhea provided a major health challenge worldwide which was one of the most important reasons for children morbidity and death. The activation of Cl– channels in intestinal epithelial cells resulting in the excessive fluid secretion in the intestine was the main reason of diarrhea caused by enterotoxins. In diarrhea caused by cholera and the other bacterial enterotoxins, cystic fibrosis transmembrane conductance regulator (CFTR) was the main cAMP-control Cl– channel to promote the fluid secretion in epithelial cells. Therefore, CFTR inhibitors were the new choices for secretory diarrhea. CFTR inhibitors included thiazolidinone, glycine hydrazide and quinoxalinedione chem. classes, and some components from natural plants also exhibited CFTR inhibition activity, however, further studies should be done.
Zhongguo Yaoshi (Wuhan, China) published new progress about 307510-92-5. 307510-92-5 belongs to thiazolidine, auxiliary class Membrane Transporter/Ion Channel,CFTR, name is 4-((4-Oxo-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-5-ylidene)methyl)benzoic acid, and the molecular formula is C9H17NO, Safety of 4-((4-Oxo-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-5-ylidene)methyl)benzoic acid.
Referemce:
https://en.wikipedia.org/wiki/Thiazolidine,
Thiazolidine – ScienceDirect.com